H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $7.00 price target on VYNE Therapeutics (NASDAQ: VYNE), following a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE